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Abstract Background and Objective: There are only a few publications on the effects of
dexamethasone on the plasma levels of cell adhesion molecules (CAMs). The
goal of this study was to investigate the effects of dexamethasone 4mg on the
perioperative plasma levels of CAMs (soluble intercellular adhesion mole-
cules [sICAM-1] and soluble vascular cell adhesion molecules [sVCAM-1])
during laparoscopic cholecystectomy.
Methods: Forty-two patients undergoing laparoscopic cholecystectomy
under total intravenous anesthesia were enrolled and randomly divided into
two groups: the first group received dexamethasone 4mg (DEX group, n= 21)
and the second group were controls (C group, n = 21). Plasma levels of
sICAM-1 and sVCAM-1 were assessed before anesthesia, after induction
(before surgery), and at 2 and 24 hours after surgery, respectively. Compar-
isons were performed for area under the plasma concentration-time curve
(AUC) and within-group values.
Results:AUC comparison for sICAM-1 showed significantly increased levels
in the C group (p = 0.036), while there was no significant difference for
sVCAM-1 (p = 0.052). Within-group analysis showed increased levels for
both sICAM-1 and sVCAM-1 in the C group at 24 hours postoperatively
(p= 0.35 and p = 0.025, respectively).
Conclusions: In our study, dexamethasone 4mg given before laparoscopic
cholecystectomy determined a significant decrease in plasma levels of sICAM-1.
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Both sICAM-1 and sVCAM-1 remained increased compared with baseline at
24 hours in the C group. This may partially explain the postoperative anti-
inflammatory effects of dexamethasone. Further studies are needed.
Introduction
Interactions between cells and different sub-
stratum are mediated through different families
of receptors, among which cell adhesion mole-
cules (CAMs) as a part of the immunoglobulin
superfamily are included. Due to their implications
in cell interactions, CAMs are involved in nu-
merous processes such as wound healing,[1,2] and
inflammatory responses such as atherosclerosis
or ischemia-reperfusion lesions.[3]
Two of the most studied CAMs are intercellular
adhesion molecules (ICAMs) and vascular cell
adhesion molecules (VCAMs). ICAMs are pres-
ent in low concentrations on the surface of leu-
kocytes and endothelial cells; they are involved in
stabilizing cell-cell interactions and in leukocyte
transmigration through the endothelial wall. Re-
cent studies have shown implications of ICAMs
as viral entry molecules and in signal trans-
duction.[4,5] VCAMs are expressed in blood ves-
sels after endothelial cell stimulation by cytokines.
VCAMs are also involved in signal transduction
and in certain inflammatory diseases such as
atherosclerosis and rheumatoid arthritis.[3]
There is limited information on the effects of
anesthesia on CAMs[6] and even less is known
about the effects of dexamethasone on these mol-
ecules. The information available refers to high
doses of corticosteroids, which have been found to
inhibit the release of ICAMs or the expression of
VCAMs due to high levels of interleukins.[7,8]
Our study was designed to investigate the ef-
fects of a small dose of dexamethasone on CAMs.
The primary outcome of this study was the eval-
uation of plasma levels of soluble intercellular
adhesion molecule-1 (sICAM-1) and soluble vas-
cular cell adhesion molecule-1 (sVCAM-1) in
patients with and without prophylactic dexa-
methasone for postoperative nausea and vomiting
(PONV) during laparoscopic cholecystectomy
under total intravenous anesthesia (TIVA).
Methods
Ethical approval was provided (No. 178C) by
the Ethics Committee of the ‘‘Iuliu Hat¸ieganu’’
University of Medicine and Pharmacy, Cluj-
Napoca, Romania, (president Prof. Dr F. Loghin)
on 19 December 2007.
After ethical approval and written informed
consent, 46 patients (American Society of Anes-
thesiologists physical status scores I or II [ASA I
and II]) undergoing laparoscopic cholecystectomy
under TIVA were included in the study. Patients
were randomly divided by a computer-generated
randomization sequence into two study groups:
the first group received dexamethasone 4mg (DEX
group, n = 23) before induction of anesthesia and
the second group were controls (C group, n= 23).
Patients with acute cholecystitis, other inflamma-
tory diseases, immune disorders, obesity (body
mass index ‡30), diabetes mellitus, allergies, gas-
tric ulcers, asthma, history of PONV, or current
use of steroid or anti-inflammatory medication
were excluded from the study. Although there is no
direct connection between CAMs and these cri-
teria, taking into consideration that both ICAMs
and VCAMs can be induced by tumor necrosis
factor and interleukin-1-X, we chose to exclude all
conditions that might interfere with the levels of
these cytokines.
Anesthetic protocol was the same in both
groups. All patients were premedicated with oral
midazolam 7.5mg. After arriving in the operat-
ing room, an intravenous cannula was inserted,
blood samples were drawn for preoperative CAMs
assessment and crystalloid 500mL infusion was
started. A second intravenous cannula was in-
serted and used for anesthetic drug administra-
tion. TIVA was induced with target-controlled
infusion – propofol at an initial plasma concen-
tration of 4 mg/mL (Orchestra Base Primea,
Fresenius Vial SAS, Bre´zins, France) and remi-
fentanil administered by manual controlled in-
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fusion with 0.5 mg/kg/min in the first minute and
0.25 mg/kg/min thereafter.
Tracheal intubation was facilitated with atra-
curium 0.6mg/kg. During maintenance of anes-
thesia propofol, plasma concentration was adjusted
tomaintain a Bispectral Index (BIS) [Spacelabs
Healthcare, Issaquah,WA, USA] between 40 and
55, and remifentanil was adjusted in 0.05mg/kg/min
steps according to patient needs.
If necessary, additional atracurium 10mg was
administered. Propofol and remifentanil infusions
were stopped after the last stitch and muscle pa-
ralysis antagonized with neostigmine 2.5mg and
atropine 1mg.
Monitoring included measurement of mean
arterial blood pressure at 4-minute intervals, heart
rate, oxygen saturation, end-tidal carbon dioxide
(CO2), peripheral temperature and BIS
. Respira-
tory rate and inspiratory pressure were adjusted to
maintain an end-tidal CO2 of 35–45mmHg.
Hypotension (defined as a decrease of blood
pressure with over 25% of baseline values) was
corrected with an increased rate of fluid administra-
tion and/or boluses of intravenous ephedrine 5mg.
The postoperative analgesia regimen included
oral paracetamol 1 g/8h and intravenous pethidine
0.4–0.5mg/kg at patients’ request or when pain
score on a visual analog scale (VAS) was ‡3 (on a
5-point VAS scale, 5=worst pain possible, 0= no
pain). PONV was treated when necessary with in-
travenous metoclopramide 10mg; if metoclopra-
mide was not efficient (nausea and vomiting after
metoclopramide), ondansetron 4mg was given.
Crystalloid 1000mL and low-molecular-weight
heparins were also included in the postoperative
prescriptions. NSAIDs were avoided because of
the interference with interleukins andCAMs levels.
Measurement of Cell Adhesion Molecules
Only sICAM-1 and sVCAM-1 were assessed
in this study. Separate dedicated kits are avail-
able for soluble intercellular adhesion molecule-2
through to soluble intercellular adhesionmolecule-5.
Blood samples for ICAM-1 and VCAM-1
measurement were collected at the following time
intervals: (i) before induction, at arrival in the
operating room (T1); (ii) before surgery, after
induction of anesthesia (T2); (iii) at 2 hours after
surgery (T3); and (iv) at 24 hours after surgery
(T4). Samples (7mL) were drawn via an indwelling
intravenous cannula inserted into a forearm vein,
collected in Vacutainer (Becton, Dickinson and
Company, Franklin Lakes, NJ, USA) tubes and
centrifuged at 2500 rpm for 10 minutes at room
temperature. Separated plasma samples (3–4mL)
were stored in cryotubes (Citotest Labware
Manufacturing Co, Ltd, China) below -30C
according to manufacturer indications until assay.
sICAM-1 and sVCAM-1 were measured using
commercially available kits (Quantikine, R&D
Systems Inc., Minneapolis, MN, USA) and a
two-step sandwich ELISA. In the first step stan-
dards and plasma samples were pipetted into the
wells of ELISA plates where CAMs are bounded
by previously coated immobilized specific anti-
bodies. Detection antibodies were added after
washing the plate. The final result of the reactions
is a yellow product whose optical density is mea-
sured and is related to the amount of the molecule
bound in the initial step. The sample values are
then read from a standard curve.
Detection limits as given by the manufacturer
are within the following ranges: sVCAM-1
0.17–1.26 (mean = 0.6) ng/mL; sICAM-1
0.049–0.254 (mean = 0.096) ng/mL, with intra-
and interassay coefficients of variation both less
than 8% (Quantikine, R&D Systems Inc., Min-
neapolis, MN, USA).
Normal plasma values of CAMs as given
by the manufacturer are within the following
ranges: sVCAM-1 349–991 ng/mL; sICAM-1
98.8–320 ng/mL.
Statistical Analysis
Statistical analysis was performed using SPSS
17.0 (SPSS Inc., Chicago, IL, USA) andMedCalc
8.3.1.1. statistical packages. We calculated a
sample size based on the results of a pilot study
(n = 5) that showed a 28%median level difference
between groups in pro-inflammatory cytokine
(interleukin-6) levels. For a type I error (alpha
level) of 0.05 and a type II error (beta level) of
0.20, we calculated a minimum required sample
size of 20 patients per group. Due to a previous
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experience from the pilot study, we estimated a
maximum loss of 15% of the enrolled patients
and this resulted in a maximum sample size of
23 patients per group. Data were tested for nor-
mality using the Kolmogorov-Smirnov test.
Longitudinal data were examined using summary
measure analysis as described.[9] Comparisons of
the area under the plasma concentration-time
curve were performed between groups using the
Mann-Whitney U test. The Wilcoxon signed-rank
test was used to assess differences between repeti-
tive measures of the same continuous variable.
Single measurement differences between the groups
were assessed using the Mann-Whitney U test or
Student’s t-test according to the normality of data.
The chi-square test was used to test correlations
between qualitative data. Continuous data were
expressed as either mean plus or minus standard
deviation or median (minimum–maximum) values,
depending on normality of data. A p-value of <0.05
was considered statistically significant.
Results
Study groups were similar with regard to demo-
graphic data (see table I). Altogether, 42 patients
completed the CAMs analysis during the first
24-hour postoperative period. Two patients were
excluded from the DEX group due to an acute
cholecystitis (diagnosed intraoperatively) and tech-
nical problems; two patients were excluded from the
C group due to technical problems (one patient was
discharged earlier than 24 hours postoperatively
and one patient had missing samples).
None of the patients became hypothermic
during surgery. Mean temperature during anes-
thesia was 36.5 – 0.288C.
In both groups all pre-induction values of
CAMs were within the normal ranges as given by
the manufacturer. Pre-induction levels did not
differ between study groups for both sICAM-1 or
sVCAM-1 (see table II).
Area under the plasma concentration-time
curve comparison between study groups revealed
significant differences for sICAM-1 (p = 0.036),
with greater levels in the C group, and insignif-
icantly greater levels for sVCAM-1 (p = 0.052), in
the DEX group (see table III).
From the plasma concentration-time curve of
CAMs as shown in figures 1 and 2, it can be seen
that the greatest variations were registered at T3
and T4. However, both sICAM-1 and sVCAM-1
variations showed less variability in the DEX
group than in the C group. This is why we pro-
ceeded with a within-group analysis.
Within-group comparisons of plasma levels of
CAMs at T3 and T4 are shown in tables IV andV,
respectively.
No significant differences were registered at
T3 in either sICAM-1 or sVCAM-1 plasma levels
when compared with baseline values in both study
groups (see table IV). However, at T4, the
sVCAM-1 levels remained significantly higher
than baseline in the C group (p = 0.025), while
sICAM-1 plasma levels were insignificantly in-
creased in the C group also (p = 0.35) [see table V].
Table I. Demographic data of the study groups
Parameter DEX group (n =21) C group (n= 21) p-Value
Age (y)a 54.00 – 14.64 50.4 –13.95 0.42
Weight (kg)a 75.85 – 14.78 79 – 7.57 0.39
Sex (F/M) 12/9 13/8 0.5
ASA I/II 9/12 11/10 0.75
Anesthesia
time (min)a
49.95 – 20.19 42.5 –5.57 0.11
IV fluids (mL)a 1214.28 – 253.54 1250 – 256.49 0.65
a Data are expressed as mean –SD.
ASA I/II =American Society of Anesthesiologists physical status
scores I or II; C = control; DEX = dexamethasone; F = female; IV =
intravenous; M =male.
Table II. Pre-induction plasma levels of cell adhesion molecules (CAMs) in study groupsa
CAM DEX group (n = 21) C group (n= 21) p-Value
sICAM-1 (pg/mL) 62.29 (31.7–76.1) 69.23 (19.6–153.3) 0.062
sVCAM-1 (pg/mL) 302.20 (209.8–389.2) 284.51 (68.0–329.3) 0.070
a Data are expressed as median (minimum–maximum).
C= control; DEX=dexamethasone; sICAM-1= soluble intercellular adhesion molecule-1; sVCAM-1= soluble vascular cell adhesion molecule-1.
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Discussion
Despite the fact that dexamethasone is used as
a routine prophylaxis for PONV, especially after
laparoscopic surgery,[10,11] for many years only
limited adverse effects were reported.[12,13] Most
of these reports focused on clinical adverse effects
such as infections, wound healing, surgical hem-
orrhage, or other effects due to corticosteroid
use.[12] As well as a decreased incidence of PONV,
there are also reports on other beneficial effects of
dexamethasone such as a decreased degree of
pain and swelling or a more rapid discharge.[14,15]
Little is known about cellular and molecular
effects of small doses of dexamethasone (e.g. those
doses used for PONV prophylaxis) or about the
effects on immune response. It has been demon-
strated that higher doses of dexamethasone de-
crease the inflammatory response after surgery,
especially after cardiac surgery.[16] This effect is
mediated by the increase in plasma levels of anti-
inflammatory interleukins and the decrease in pro-
inflammatory interleukins. Less is known about
the effects of high-dose dexamethasone on CAMs
(ICAMs, VCAMs).[7,8,17,18] The effects of a small
dose of dexamethasone on CAMs have not been
studied until now.
Apart from the effects of different CAMs on
wound healing[1,2] or during the aforementioned
inflammatory responses, such as atherosclerosis
or ischemia-reperfusion lesions,[3] there are a few
other important clinical effects related to in-
flammation or tumor progression. It has been
shown that CAMs are involved in tumor pro-
gression and metastasis.[19-21] However, the im-
plication of CAMs in these processes is evaluated
differently in different studies. Some studies mea-
sure soluble forms[20] or expression of CAMs,[1,3]
while other studies evaluate CAMs as whole mole-
cules.[1,19,21]
ICAMs and VCAMs are members of the im-
munoglobulin superfamily regulated by the in-
flammatory interleukins.[22]
ICAM-1 has five domains in its extracellular
domain and soluble forms of mono- and dimeric
ICAM-1 generated by proteolytic cleavage known
as sICAM-1were determined in our study. VCAMs
also have extracellular domains and the soluble
form that can be determined in plasma (sVCAM-1)
also results from proteolytic cleavage.
The mechanisms involved in actions of CAMs
are different for ICAM-1 and for VCAM-1.
Table III. Results of between-group longitudinal comparisons of plasma levels of cell adhesion molecules (CAMs) in study groups
CAM DEX group (n= 21) C group (n= 21) p-Value
AUCa 95% CI AUCa 95% CI
sICAM-1 187.35 151.29, 198.52 227.74 162.23, 324.62 0.036
sVCAM-1 884.84 833.02, 1092.09 843.31 787.87, 918.17 0.052
a AUC was calculated having baseline as common reference for both groups. Between-group longitudinal comparisons were performed
using the Mann-Whitney U test.
AUC = area under the plasma concentration-time curve; C = control; DEX =dexamethasone; sICAM-1 = soluble intercellular adhesion

















T1 T2 T3 T4
C group
DEX group
Fig. 1. Plasma concentrations of soluble intercellular adhesion
molecule (sICAM)-1 expressed as median (interquartile range).
C = control; DEX = dexamethasone; T1 =before induction; T2 =
immediately after induction; T3 = at 2 hours after skin closure; T4 = at
24 hours after skin closure.
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ICAM-1 produces its effects by promoting re-
cruitment and adhesion of leukocytes to the ac-
tivated endothelium due to strong bonds with
integrins, thus trapping the inflammatory cells to
the vascular surface and promoting migration
through endothelial cells.[23] On the other side, a
decreased level of ICAM-1 may allow tumor cells
to enter from the tissues into the vessel, thus
promoting metastasis. VCAM-1 is produced
mainly by the endothelial cells and other types of
cells (i.e. smooth muscle cells) after being stimu-
lated by the interleukins and it promotes adhe-
sion of inflammatory cells to the vascular wall
and subsequent migration.[20,24] Some of the tu-
mor cells may also use VCAM-1 to adhere to the
vascular wall and to migrate.[25-27]
CAMs are affected by surgery and, in turn, may
influence outcome after oncologic surgery.[26-28]
There are only a few studies on the effect of lap-
aroscopic surgery on the level of CAMs. Lap-
aroscopic surgery is well recognized as being able
to reduce the amplitude of the inflammatory
response,[29,30] so, theoretically, the levels of
CAMs should also be reduced. However, when
the levels of CAMs are the primary outcome
parameter, the influence of CO2 and the pressure
of pneumoperitoneum must be taken into con-
sideration as these may influence the levels of
CAMs.[31,32] Attention must also be paid to the
difference between plasma levels on one side and
mucosal or peritoneal/mesenchymal levels of CAMs
on the other side during laparoscopic surgery.[30,31]
Regarding the effects of dexamethasone on
plasma levels of CAMs, the available data are
conflicting. According to some studies, dexa-
methasone decreases the levels of CAMs,[17,33]
while others have shown that dexamethasone
does not influence the CAMs level or that dexa-
methasone only reduces the increased expression
of CAMs due to an increased level of pro-
inflammatory interleukins.[17,33-35] Most studies
have focused on expression of ICAM-1 and
VCAM-1; as the CAMs evaluation differs, it is
difficult to compare different studies.
Our study showed that even a small dose of
dexamethasone influenced the plasma levels of
sICAM-1 and sVCAM-1. The difference is sig-
nificant for sICAM-1 and did not reach statistical
significance for sVCAM-1. Although there are
not similar studies with such a low dose of dexa-
methasone used as prophylaxis for PONV during
laparoscopic cholecystectomy, and the measured














T1 T2 T3 T4
C group
DEX group
Fig. 2. Plasma concentrations of soluble vascular cell adhesion
molecule (sVCAM)-1 expressed as median (interquartile range).
C = control; DEX = dexamethasone; T1 =before induction; T2 =
immediately after induction; T3 = at 2 hours after skin closure; T4 =at
24 hours after skin closure.
Table IV. Plasma levels of cell adhesion molecules (CAMs) in study groups: within-group comparison of values at 2 hours postoperatively
with baseline valuesa
CAM DEX group (n =21) p-Value C group (n =21) p-Value
T1 T3 (DEX group) T1 T3 (C group)
sICAM-1 62.3 (31.7–76.1) 62.4 (29.3–75.9) 0.426 69.23 (19.66–153.3) 74.75 (18.2–160.6) 0.911
sVCAM-1 302.2 (209.8–389.2) 306.77 (199.5–388.2) 0.758 284.51 (68.0–329.3) 275.33 (116.4–323.0) 0.279
a Data are expressed as median (minimum–maximum).
C= control; DEX=dexamethasone; sICAM-1= soluble intercellular adhesion molecule-1; sVCAM-1= soluble vascular cell adhesion molecule-1;
T1= before induction; T3= at 2 hours after skin closure.
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forms; in the others, expression of ICAM-1 and
VCAM- 1), our results are similar to those of
Cronstein et al.[33] and Aziz and Wakefield,[34]
showing that in vitro dexamethasone decreases
the expression of CAMs induced by the in-
flammatory interleukins, and different from
those of Dufour et al.,[35] who did not find an
effect of dexamethasone on the level of CAMs.
Regarding the increased levels of sICAM-1 and
sVCAM-1 at 24 hours postoperatively, these may
be at least partially determined by the increased
postoperative levels of pro-inflammatory inter-
leukins in the absence of dexamethasone de-
scribed so far in the literature.
Our study had some limitations. First, the
number of studied patients was small. With a
larger number of patients, the results for CAMs
might have been different. The sample size was
calculated based on differences in interleukin-6
plasma levels in the pilot study, so our results
may be underpowered with respect to sICAM-1
and sVCAM-1 levels.
We measured only soluble levels of ICAM-1
and VCAM-1; the effect of dexamethasone on
expression of CAMs as transmembrane forms
may be different. On the other side, we focused
our study on plasma levels of CAMs; peritoneal
levels may follow a different pattern.
Conclusions
In conclusion, our study has shown that even
a small dose of dexamethasone may decrease
the level of sICAM, while the results for sVCAM
did not reach statistical significance. Although
CAMs are only part of the immune response,
together with interleukins, they can at least par-
tially explain the beneficial anti-inflammatory
effects of dexamethasone reported so far. The
clinical relevance of these results is unclear and
further studies on larger groups of patients are
needed to further elucidate the effects of a small
dose of dexamethasone on CAMs and their clin-
ical significance.
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